- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04471142
Effectiveness of Compressive Bandage Use in Seroma Prevention
September 20, 2021 updated by: Erica Alves Nogueira Fabro, Instituto Nacional de Cancer, Brazil
Effectiveness of Compressive Bandage Use in Post-Treatment Seroma Prevention Breast Cancer Surgery
INTRODUCTION: Seroma is the most common complication after surgical treatment for breast cancer.
It is the abnormal accumulation of serous fluid that develops under skin flaps and may be associated with necrosis, dehiscence, sepsis, and shoulder dysfunction.
The therapeutic bandage has been inserted in clinical practice because it is similar to the elasticity of the skin and is able to help the circulatory and lymphatic system, reduce pain and local swelling, and may have benefits for prevention and treatment of seroma when applied compressively. .
OBJECTIVE: To evaluate the effectiveness of compressive bandage in preventing seroma.
METHODOLOGY: Randomized study of women over 18 years who underwent mastectomy at HCIII / INCA.
Eligible patients will be allocated to the intervention and control groups by lot (270 envelopes, 135 patients per group).
The intervention group, in addition to the use of the drain, will be submitted to the compression bandage on the day of hospital discharge and will be reevaluated on the seventh day.
The control group will follow the institutional routine, using only the drain.
The incidence and volume of the seroma, as well as the length of stay of the drain will be evaluated after 30 days through the medical record.
Symptoms and skin changes resulting from the use of the bandage will be evaluated through a specific form.
ANALYSIS: Descriptive analysis will be by measures of central tendency, dispersion and frequency distribution.
Outcome assessment will be performed by odds ratio (for categorical variables) and by mean difference (Student's t-test), considering a 95% confidence interval.
To control the confounding variables, multiple logistic regression (categorical outcome) and multiple linear regression (continuous outcome) will be performed by the Stepwise Forward method, including variables with p <0.20.
Study Overview
Detailed Description
This is a randomized clinical trial with women undergoing surgical treatment for breast cancer at Cancer Hospital III / INCA.
All patients undergoing mastectomy will be evaluated for eligibility criteria after the first dressing in the hospital, those considered eligible will be informed about the study and no obligation to participate through free and informed consent.
Upon acceptance, patients will be randomized to the intervention or control group, which will be performed by lot at the time the patient enters the study.
27 blocks will be available containing 10 envelopes where 05 will contain a code that allocates the patients in group A and 05 in group B. This choice was chosen to avoid influences of the therapist or patient's preference over the intervention.
The patients will be oriented in relation to the group they are inserted and what monitoring will be performed while the patient is under the care of the dressing.
All evaluations, intervention and data collection will be performed by trained professionals qualified for this purpose.
Group A: intervention group with preventive application of compressive bandage in addition to the suction drain (routine adopted in the institution).
Patients allocated to this group on the day of the first dressing, before hospital discharge, according to the institutional routine, are instructed by the nursing staff to wash the plastron region with cold, boiled filtered water and to return within one week at the outpatient clinic.
The bandage will be applied on the day of discharge after the first dressing, withdrawal and new bandage applied on the fourth day and definitive removal on the seventh day when it will be scheduled for return in nursing care.
Should any complications occur due to the use of the bandage, the patients will be advised to remove the material at home and will be suspended from the research protocol.
At the end of the seven days, the patients will be reevaluated.
Prior to the application of the bandage will be made the antisepsis of the skin and placement of the transparent and sterile film dressing over the region of the scar points to protect the scar.
The 5 cm wide Vitaltape® neuromuscular bandage will be used with maximum stretching over the plastron region and finished with two ends of two to three centimeters without stretching.
As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
All applications will be performed by the same physical therapist.
Group B: control group.
The patient will follow the institution's routine only with the suction drain.
All patients will be instructed to do the same care with the suction drain according to the institutional routine.
Study Type
Interventional
Enrollment (Anticipated)
270
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Erica Fabro, Master
- Phone Number: 55 21 993971746
- Email: efabro@inca.gov.br
Study Contact Backup
- Name: Anke Bergamnn, Doctor
- Phone Number: 55 21 32076551
- Email: abergmann@inca.gov.br
Study Locations
-
-
-
Rio de Janeiro, Brazil, 20530-003
- Erica Alves Nogueira Fabro
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women aged 18 and over
- underwent mastectomy assurgical treatment for breast cancer.
Exclusion Criteria:
- bilateral breast cancer;
- patient undergoing neoadjuvant radiotherapy;
- infection in the surgical wound or hematoma;
- autoimmune disease reporting (dermatomyositis, hidradenitis suppurativa, nephropathy, lupus erythematosus, morphea, psoriasis, pemphigus vulgaris, scleroderma);
- patients with difficulties in understanding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Intervention group with preventive application of compressive bandages in addition to suction drain (routine adopted at the institution).
|
After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied.
For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching.
As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
Other Names:
|
No Intervention: Group B
Group control.
The patient will follow the institution's routine with only the suction drain.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroma Incidence
Time Frame: 30 days
|
the presence of assessed local fluctuation will be considered seroma by the nursing team during dressing care, with indication of puncture aspiration to resolve the condition, regardless of the volume drained.
|
30 days
|
Seroma volume
Time Frame: 30 days
|
the total volume drained and the number of aspirations will be considered necessary until resolution of the picture.
|
30 days
|
Permanence time with the Suction Drain
Time Frame: 15 days
|
The permanence time (in days) will be checked with the suction drain, as reported by the dressing team.
|
15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of the use of the compressive bandage in mastectomized women
Time Frame: 7 days
|
The dermal changes will be evaluated at the location of the bandage application of the 135 participants in the intervention group, such as discoloration, increased local temperature, skin peeling, presence of a wound and formation of bullous lesions at the site of the application of the neuromuscular bandage, graded in light, moderate or severe, according to the severity of the change, from a semi-structured questionnaire.
|
7 days
|
To assess the tolerance reported by the patient to the use of compressive taping
Time Frame: 7 days
|
The symptoms of pain, itching, burning, discomfort, tightness, increased fluctuation of the seroma at the site of application of the bandage of the 135 participants will be evaluated.
The symptoms will be graded according to the Visual Numeric Scale (0-10), where 0 will be considered no sensation and 10 unbearable sensation with the use of the bandage.
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Erica Fabro, Master, INCA - Brazil
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 8, 2021
Primary Completion (Anticipated)
June 30, 2022
Study Completion (Anticipated)
March 30, 2023
Study Registration Dates
First Submitted
July 10, 2020
First Submitted That Met QC Criteria
July 10, 2020
First Posted (Actual)
July 15, 2020
Study Record Updates
Last Update Posted (Actual)
September 21, 2021
Last Update Submitted That Met QC Criteria
September 20, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Instituto Nacional do Câncer
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seroma
-
Omphis FoundationConsorci Sanitari del MaresmeRecruitingSeroma Following ProcedureSpain
-
Zagazig UniversityCompletedPost-mastectomty SeromaEgypt
-
Anselm TamminenNot yet recruitingSeroma Complicating A Procedure
-
SOMAVAC Medical SolutionsUniversity of TennesseeUnknownHematoma Postoperative | Seroma as Procedural ComplicationUnited States
-
Michigan State UniversityCompletedInfected Seroma After Surgical ProcedureUnited States
-
Severance HospitalCompletedSeroma as Procedural ComplicationKorea, Republic of
-
Ikechukwu Bartholomew UlasiCompleted
-
Hamilton Health Sciences CorporationRecruitingBreast Cancer | Seroma Complicating A Procedure | Hematoma PostoperativeCanada
-
Zuyderland Medisch CentrumNot yet recruiting
-
University of California, San FranciscoDavol Inc.Completed
Clinical Trials on neuromuscular bandage
-
Medical University of ViennaOutcomes Research ConsortiumTerminated
-
University Hospital, ToulouseRecruiting
-
Universidade Norte do ParanáCompleted
-
Johnson & Johnson Consumer Inc. (J&JCI)CompletedWound HealingUnited States
-
Goldman, Butterwick, Fitzpatrick and GroffCompletedExposure LaserUnited States
-
University of AlcalaCompleted
-
Hospital Clinic of BarcelonaCompleted
-
Mahidol UniversityCompletedVenous InsufficiencyThailand
-
Abant Izzet Baysal UniversityCompletedBreast Cancer Lymphedema | Lymphedema of Upper Limb | Edema ArmTurkey
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed